A Phase 2 interventional study of Selinexor (KPT-330) in Squamous Cell Carcinoma, sponsored by Karyopharm Therapeutics Inc. Terminated at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 330 studies in Carcinoma, Squamous Cell with a site in United States — 68 open to participants now, 99 under way, 6 of them phase 3. Carcinoma, Squamous Cell · United States.
Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, this one is the 120th largest by enrollment of the 280 interventional ones that give a count, is one of 17 that started in 2014, is one of 106 in phase 2, and was the 139th registered.
629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.
Browse Carcinoma, Squamous Cell studies →68 of the 330 studies in Carcinoma, Squamous Cell with a site in United States are open now. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Rockefeller University · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
330 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 108 · Phase 2 138 · Phase 3 28 · Phase 4 4
First in 1994; this study’s year is marked. 17 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is close to the median of 45 across 478 interventional studies indexed under Carcinoma, Squamous Cell.
Median enrollment 37 across the 280 interventional studies, 64 across the 45 observational. Of the 203 that completed or were terminated, 94 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 330 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 2 studies filed under Carcinoma, Squamous Cell — fewer than ten, so there is no comparison to draw.
31 of the studies in Carcinoma, Squamous Cell with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT07931664The Center for Clinical and Cosmetic ResearchEvaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. | 2026-11 |
| NCT06615635Alpha Tau Medical LTD.Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients | 2026-12 |
| NCT05863052University of OklahomaAnalyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | 2026-12-31 |
| NCT05366166UNC Lineberger Comprehensive Cancer CenterPembrolizumab Plus Olaparib in LA-HNSCC | 2027-01-21 |
Add all 31 to your calendar (.ics) → With an account.
Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.
This is a multicenter, open-label, single-arm Phase 2 study of the SINE selinexor given orally to patients diagnosed with advanced SCC of the head and neck, lung, or esophagus who have experienced relapse and/or metastasis following multiple prior chemotherapy treatments (\<2 lines of therapy).
Patients will receive fixed doses of selinexor tablets twice weekly in 28-day cycles. Patients may continue from one cycle to the next without interruption as along as all criteria are met and no reason for discontinuation occurs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced squamous cell carcinoma (SCC) of head and neck, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 milligram (mg) selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets less than \[\<\] 100\*10\^9 per litre \[/L\]), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
Drug: Selinexor (KPT-330)
Participants with advanced SCC of lungs, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets \<100\*10\^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
Drug: Selinexor (KPT-330)
Participants with advanced SCC of esophagus, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets \<100\*10\^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
Drug: Selinexor (KPT-330)
Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
Also known as: KPT-330
Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
DCR was defined as the best overall response of complete response (CR), partial response (PR), or stable disease (SD). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participant response was evaluated by physical examinations and computed tomography (CT)/Magnetic Resonance Imaging (MRI) (or optional positron emission tomography \[PET\]/CT) and assessed by RECIST 1.1 criteria.
Time frame: up to 14.6 months
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event (AE) was defined as any unfavorable sign and unintended sign (including abnormal laboratory finding), symptom, or disease temporarily associated with the use of the study drug, whether or not related to study drug. An SAE was defined as any untoward medical occurrence that occurs at any dose (including after informed consent was signed and prior to dosing) that resulted in death, was life-threatening (participant was at immediate risk of death from event), required in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect, and important medical events. A TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after first dose of treatment through 30 days following last dose of study treatment, or any event considered drug-related by investigator through end of study.
Time frame: From the first administration of study drug up to 30 days follow-up (up to 14.6 months)
Number of Participants With Treatment-emergent Adverse Events by Severity: Clinical Terminology Categories for Adverse Events (CTCAE) Grading Scale
AE:Any unfavorable sign and unintended sign,symptom, or disease temporarily associated with use of study drug, whether or not related to it. SAE:Any untoward medical occurrence that occurs at any dose (after informed consent was signed, prior dosing) that resulted in death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and important medical events. TEAE:Any AE with onset or worsening of existing condition on or after first dose through 30 days following last dose of study drug, or any event considered drug-related by investigator through end of study. Severity(Grades 1 to 5) of each AE was categorized as either mild=1(transient,does not interfere with daily activities), moderate=2(low level of inconvenience or concern,interfere with daily activities), severe=3(interrupt usual daily activities), life threatening=4 or fatal=5, higher grade reported worst outcome.
Time frame: From the first administration of study drug up to 30 days follow-up (up to 14.6 months)
The study was conducted at 14 sites in United States and 1 site in Canada between 22 September 2014 and 10 December 2015.
| Milestone | Cohort 1: Head and Neck-SCC | Cohort 2: Lungs-SCC | Cohort 3: Esophagus-SCC |
|---|---|---|---|
| Started | 37 | 5 | 3 |
| Treated | 33 | 4 | 1 |
| Completed | 0 | 0 | 0 |
| Not completed | 37 | 5 | 3 |
| Withdrew: Participant discontinued study therapy | 2 | 0 | 0 |
| Withdrew: Participant withdrew informed consent | 2 | 1 | 2 |
| Withdrew: Disease progression | 11 | 2 | 0 |
| Withdrew: Adverse event (ae) | 1 | 0 | 0 |
| Withdrew: Death | 16 | 2 | 1 |
| Withdrew: Other | 5 | 0 | 0 |
DCR was defined as the best overall response of complete response (CR), partial response (PR), or stable disease (SD). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participant response was evaluated by physical examinations and computed tomography (CT)/Magnetic Resonance Imaging (MRI) (or optional positron emission tomography \[PET\]/CT) and assessed by RECIST 1.1 criteria.
| percentage of participants | Cohort 1: Head and Neck-SCC | Cohort 2: Lungs-SCC | Cohort 3: Esophagus-SCC |
|---|---|---|---|
| Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | 21.2 (10.7 to 37.8) | 0.0 (0.0 to 49.0) | 0.0 (0.0 to 79.3) |
An adverse event (AE) was defined as any unfavorable sign and unintended sign (including abnormal laboratory finding), symptom, or disease temporarily associated with the use of the study drug, whether or not related to study drug. An SAE was defined as any untoward medical occurrence that occurs at any dose (including after informed consent was signed and prior to dosing) that resulted in death, was life-threatening (participant was at immediate risk of death from event), required in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect, and important medical events. A TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after first dose of treatment through 30 days following last dose of study treatment, or any event considered drug-related by investigator through end of study.
| Participants | Cohort 1: Head and Neck-SCC | Cohort 2: Lungs-SCC | Cohort 3: Esophagus-SCC |
|---|---|---|---|
| Participants with TEAEs | 37 | 5 | 3 |
| Participants with SAEs | 18 | 2 | 3 |
AE:Any unfavorable sign and unintended sign,symptom, or disease temporarily associated with use of study drug, whether or not related to it. SAE:Any untoward medical occurrence that occurs at any dose (after informed consent was signed, prior dosing) that resulted in death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and important medical events. TEAE:Any AE with onset or worsening of existing condition on or after first dose through 30 days following last dose of study drug, or any event considered drug-related by investigator through end of study. Severity(Grades 1 to 5) of each AE was categorized as either mild=1(transient,does not interfere with daily activities), moderate=2(low level of inconvenience or concern,interfere with daily activities), severe=3(interrupt usual daily activities), life threatening=4 or fatal=5, higher grade reported worst outcome.
| Participants | Cohort 1: Head and Neck-SCC | Cohort 2: Lungs-SCC | Cohort 3: Esophagus-SCC |
|---|---|---|---|
| Mild (Grade 1) | 3 | 0 | 0 |
| Moderate (Grade 2) | 9 | 1 | 0 |
| Severe (Grade 3) | 21 | 4 | 3 |
| Life Threatening (Grade 4) | 3 | 0 | 0 |
| Fatal (Grade 5) | 1 | 0 | 0 |
Collected over From the first administration of study drug up to 30 days after participant's last visit (up to 14.6 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Head and Neck-SCC | 16/37 (43.2%) | 18/37 (48.6%) | 35/37 (94.6%) |
| Cohort 2: Lungs-SCC | 2/5 (40%) | 2/5 (40%) | 5/5 (100%) |
| Esophagus-SCC | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Event | Cohort 1: Head and Neck-SCC | Cohort 2: Lungs-SCC | Esophagus-SCC |
|---|---|---|---|
| TracheitisInfections and infestations | 0/37 | 0/5 | 2/3 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/37 | 0/5 | 1/3 |
| Platelet Count DecreasedInvestigations | 0/37 | 0/5 | 1/3 |
| PneumoniaInfections and infestations | 5/37 | 1/5 | 0/3 |
| DeliriumPsychiatric disorders | 1/37 | 1/5 | 0/3 |
| Lung InfectionInfections and infestations | 2/37 | 0/5 | 0/3 |
| Mouth HaemorrhageGastrointestinal disorders | 2/37 | 0/5 | 0/3 |
| Arthritis BacterialInfections and infestations | 1/37 | 0/5 | 0/3 |
| Skin InfectionInfections and infestations | 1/37 | 0/5 | 0/3 |
| Streptococcal BacteraemiaInfections and infestations | 1/37 | 0/5 | 0/3 |
| Event | Cohort 1: Head and Neck-SCC | Cohort 2: Lungs-SCC | Esophagus-SCC |
|---|---|---|---|
| NauseaGastrointestinal disorders | 25/37 | 4/5 | 0/3 |
| FatigueGeneral disorders | 21/37 | 4/5 | 1/3 |
| PyrexiaGeneral disorders | 3/37 | 0/5 | 2/3 |
| AnaemiaBlood and lymphatic system disorders | 9/37 | 1/5 | 2/3 |
| HyponatraemiaMetabolism and nutrition disorders | 15/37 | 1/5 | 1/3 |
| VomitingGastrointestinal disorders | 13/37 | 2/5 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 5/37 | 2/5 | 1/3 |
| Decreased AppetiteMetabolism and nutrition disorders | 12/37 | 2/5 | 1/3 |
| Vision BlurredEye disorders | 6/37 | 2/5 | 0/3 |
| ConstipationGastrointestinal disorders | 10/37 | 1/5 | 1/3 |
Modified intent-to-treat population (mITT) population included all participants who had received at least one dose of study drug and had at least one post baseline efficacy assessment were included if discontinuation was due to disease progression, study drug related toxicity, or death.
| Age, Continuous(years) | Cohort 1: Head and Neck-SCC | Cohort 2: Lungs-SCC | Cohort 3: Esophagus-SCC | Total |
|---|---|---|---|---|
| Mean | 58.5 ± 10.05 | 66.3 ± 6.34 | 51.0 ± NA | 59.1 ± 9.91 |
| Sex: Female, Male(Participants) | Cohort 1: Head and Neck-SCC | Cohort 2: Lungs-SCC | Cohort 3: Esophagus-SCC | Total |
|---|---|---|---|---|
| Female | 3 | 1 | 0 | 4 |
| Male | 30 | 3 | 1 | 34 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Head and Neck-SCC | Cohort 2: Lungs-SCC | Cohort 3: Esophagus-SCC | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race — Asian | 1 | 0 | 0 | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Race — Black or African American | 0 | 0 | 0 | 0 |
| Race — White | 30 | 4 | 1 | 35 |
| Race — Other-unspecified | 1 | 0 | 0 | 1 |
| Race — Unknown or Not Reported | 1 | 0 | 0 | 1 |
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2014 to primary completion in Dec 2015, 14 months.
Results were first posted in Dec 2020, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor